Johnson & Johnson said on June 15, 2026 that it will put more than $1 billion into its Jacksonville, Florida operations, primarily to expand production and distribution of its Acuvue contact lenses. The project covers a new distribution facility and new manufacturing and packaging technology meant to grow Acuvue capacity. The Jacksonville plant already produces more than 1.7 billion Acuvue lenses a year for U.S. patients.
This is the latest disclosed piece of a $55 billion U.S. investment commitment J&J announced earlier and has been rolling out in stages over recent months, according to Fierce Biotech's recap of the release. The company is treating Jacksonville as a medtech and vision care outlay, not a pharmaceutical one, and has framed the spending as a way to grow U.S. capacity for a contact lens line the company already produces at scale at home.
The workforce question is the part the announcement is built not to answer. J&J did not disclose expected new jobs at the Jacksonville site, a construction timeline, a completion date, or how large a share of the $55 billion total this slice represents. The dollar figure, the capacity figure, and the framing of the investment all come from J&J's own release, restated the same morning by Fierce Biotech. Independent verification of the headline number, the timeline, and any workforce impact has not been published.
That gap is the real shape of the story. A company commits a billion dollars to a U.S. factory. The capital number is large enough to be news. The jobs number, the timeline, and the share of the larger $55 billion program are all softer, and the announcement language is built to keep them that way. The data point worth watching next is what happens to Jacksonville's headcount as the new capacity comes online. Until that number shows up, the announcement tells the reader the size of the check, not the size of the bet.